IN THE CLAIMS

Please cancel Claims 10,13, 19, 24, 29, 31, 35, 37, 38, 39.

Please amend Claims 1, 3, 4, 5, 9, 11, 12, 14, 15, 16, 17, 18, 20, 21, 22, 23, 25, 30, 32, 33, 34, 36.

Please add new claims 40 through 45.

AMENDMENTS TO THE CLAIMS

Claim 1. (Currently Amended) A Compound of the structural formula I:

Formula I





~~(a)~~ R1 is ~~selected from the group consisting of~~ hydrogen, ~~C_1-C_8-alkyl, C_3-C_6-cycloalkyl, aryl-C_{0-4}-alkyl, heteroaryl-C_{0-4}-alkyl, aminoC_1-C_4alkyl, C_3-C_6-cycloalkylaryl-C_{0-2}-alkyl, arylheteroC_1-C_8alkyl, -CHC(O)C_1-C_4-alkoxy, C_{0-4}-alkyl-C(O)heteroC_1-C_8alkyl, and -CH_2-C(O)-R15-R16; and which C_1-C_8-alkyl, C_3-C_6-cycloalkyl, aryl-C_{0-4}-alkyl, heteroaryl-C_{0-4}-alkyl, aminoC_1-C_4alkyl, C_3-C_6-cycloalkylaryl-C_{0-2}-alkyl, arylheteroC_1-C_8alkyl, -CHC(O)C_1-C_4-alkoxy, C_{0-4}-alkyl-C(O)heteroC_1-C_8alkyl and -CH_2-C(O)-R15-R16 are each independently unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of R1'; and wherein R15 is O or NH and R16 is C_1-C_2-alkyl or benzyl, which C_1-C_2-alkyl or benzyl are each unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of R16';~~ or R1 and R2 together form a ring selected from the group consisting of piperidine, piperazine, and dihydroisoquinoline wherein said piperidine, piperazine and

dihydroisoquinoline is unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of C1-C4 alkyl, phenyl, halophenyl, trifluromethylphen, methylphenyl, acetglphenyl, benzyl, halobenzyl, benzoyl, halobenzoyl, trifluoromethylbenz, methylbenzoyl, methoxybenzoyl, acetylbenzoyl, biphenylmethylene, (phenyl)(halophenyl) methyle, and bihalophenylmethylem.

(b) R1' and R2' are each independently selected from a group consisting of C_1-C_5 alkyl, C_3-C_6 cycloalkyl, C_1-C_5 alkoxy, arylC_0-C_2alkoxy, haloC_1-C_3alkyl, halo, aryl, -C(O)C_1-C_5alkyl, -C(O)-aryl, haloC_1-C_5alkyloxy, arylC_1-C_5alkyl, and biarylC_1-C_5alkyl; and which -C(O)-aryl is unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of halo, C_1-C_5 alkyl, haloC_1-C_5 alkyl, C_1-C_5 alkoxy, and –C(O)C_1-C_5alkyl; and which C_1-C_5 alkyl, arylC_1-C_5alkyl, biarylC_1-C_5alkyl, and aryl are each independently unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of halo, C_1-C_8alkyl, aryl, haloC_1-C_5 alkyl, trihaloC_1-C_3alkyl, C_1-C_5alkoxy, and arylC_1-C_5alkyl; and which aryl is unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of halo, C_1-C_8alkyl, aryl, haloC_1-C_5 alkyl, trihaloC_1-C_3alkyl, C_1-C_5alkoxy, and arylC_1-C_5alkyl;

(c) R2 is selected from the group consisting of C_1-C_8 alkyl, C_3-C_6 cycloalkyl, aryl-C_{0-4}-alkyl, heteroaryl-C_{0-4}-alkyl, hetoC_1-C_6cycloalkylaryl, hetoC_1-C_6cycloalkylarylC1-C4alkyl, aminonoC_1-C_4alkyl, C_3-C_6 cycloalkylaryl-C_{0-2}-alkyl, arylheteroC_1-C_8alkyl, C_{0-4}-alkyl-C(O)heteroC_1-C_8alkyl, -CH(C(O)OCH$_3$)benzyl, and -CH$_2$-C(O)-R15''-R16'', and which C_1-C_8 alkyl, C_3-C_6 cycloalkyl, aryl-C_{0-4}-alkyl, hetoC_1-C_6cycloalkylaryl, hetoC_1-C_6cycloalkylarylC1-C4alkyl, heteroaryl-C_{0-4}-alkyl, aminoC_1-C_4alkyl, C_3-C_6 cycloalkylaryl-C_{0-2}-alkyl, arylheteroC_1-C_8alkyl, C_{0-4}-alkyl-C(O)heteroC_1-C_8alkyl, and -CH$_2$-C(O)-R15''-R16'' are each independently unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of R2';

(d) R15'' is O or NH;

(e) R16'' is C_1-C_2 alkyl or benzyl which C_1-C_2 alkyl and benzyl are each unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of R16';

(f) R1 and R2 together may form a heterocyclic ring which heterocyclic ring is unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of R1' and which heterocyclic ring is optionally fused with an aryl;

~~(g) E is selected from the group consisting of C(R3)(R4)A, $(CH_2)_n$ COOR13, aryl C_{0-4}-alkyl, thio C_1-C_4-alkyl, thioaryl, arylC_1-C_4alkoxy, C_1-C_4alkoxy C_1-C_4alkyl, aminoaryl, and amino C_1-C_4alkyl; and which $(CH_2)_n$ COOR13, aryl C_{0-4}-alkyl, thio- C_1-C_4-alkyl, thioaryl, C_1-C_4alkoxyaryl, C_1-C_4alkoxyC_1-C_4alkyl, aminoaryl, and aminoC_{1-4}alkyl are each independently unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of E';~~

(h) R7' and R7'' are each independently selected from the group consisting of C_1-C_4 alkyl and C_1-C_4 haloalkyl;

(i) n and m are each independently selected from the group consisting of 0, 1, 2 and 3;

(j) A is selected from the group consisting of $(CH_2)_m$ COOR14, C_1-C_3alkylnitrile, carboxamide, sulfonamide, acylsulfonamide and tetrazole, and which sulfonamide, acylsulfonamide and tetrazole are each independently unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of A';

(k) A' is a group consisting of C_1-C_4alkyl, C_1-C_4 haloalkyl, heteroaryl, and aryl, and wherein heteroaryl and aryl are each independently unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of halo, C_1-C_5 alkyl, C_1-C_5 haloalkyl, C_1-C_5 alkoxy, and –C(O) C_1-C_5 alkyl;

(l) R3 is selected from the group consisting of H, C_1-C_5 alkyl, C_1-C_5 alkenyl, and C_1-C_6 alkoxy;

(m) R4 is selected from the group consisting of H, halo, C_1-C_5 alkyl, C_1-C_6 alkoxy, C_3-C_6 cycloalkyl, aryl C_0-C_4 alkyl, and C_{0-4}alkoxyaryl, and which C_1-C_5 alkyl, C_1-C_5 alkoxy, C_3-C_6 cycloalkyl, aryl C_0-C_4 alkyl, and C_{0-4}alkoxyaryl are each independently unsubstituted or each independently substituted with from one to four substituents each independently selected from R4'; or R3 and R4 are combined to form a C_3-C_6 cycloalkyl;

(n) R5 and R6 are each independently selected from the group consisting of hydrogen, C_1-C_8 alkyl, aryl-C_{0-4}-alkyl, heteroaryl-C_{0-4}-alkyl, C_3-C_6 cycloalkylaryl-C_{0-2}-alkyl, C_3-C_6 cycloalkyl-C_{0-2}-alkyl, and -CH_2-C(O)-R17-R18, and which C_1-C_8 alkyl, aryl-C_{0-4}-alkyl, heteroaryl-C_{0-4}-alkyl, C_3-C_6 cycloalkylaryl-C_{0-2}-alkyl, C_3-C_6 cycloalkyl-C_{0-2}-alkyl, and -CH_2-C(O)-R17-R18 are each independently unsubstituted or substituted with from one to four substituents each independently selected from the group consisting of R5';

(o) ~~E',~~ R4', R5', and R13'' are each independently a group consisting of C1-C5 alkyl, C1-C5 alkoxy, C1-C5 haloalkyl, C1-C5 haloalkoxy, nitro, cyano, CHO, hydroxy, C_1-C_4 alkanoic acid, phenyl, aryloxy, SO_2R7', SR7'', arylC_0-C_2alkoxy, C1-C6alkylcarboxamido, and COOH;

(p) R16' is a group consisting of halo, C_1-C_8alkyl, aryl, haloalkyl, trihaloC_1-C_3alkyl, C_1-C_5alkoxy, and arylC_1-C_5alkyl;

(q) R17 and R18 are each independently selected from C_1-C_8 alkyl, aryl-C_{0-4}-alkyl, heteroaryl-C_{0-4}-alkyl, C_3-C_6 cycloalkylaryl-C_{0-2}-alkyl, and C_3-C_6 cycloalkyl-C_{0-2}-alkyl;

(r) ~~R13 and~~ R14 ~~are each independently~~ is selected from the group consisting of hydrogen, C1-C4alkyl, aryl, and arylmethyl, and which C1-C4alkyl are each independently unsubstituted or independently substituted with from one to three substituents each independently selected from the group consisting of R13' and which arylmethyl and aryl are each independently unsubstituted or independently substituted with from one to three substituents each independently selected from the group consisting of R14';

(s) R13' is a group consisting of C_1-C_5 alkyl, C_3-C_6 cycloalkyl, C_1-C_5 haloalkyl, C_1-C_5 alkoxy, aryloxy, halo, aryl, –C(O)C_1-C_5alkyl, -C(O)-aryl, haloC_1-C_5alkyloxy, aryl C_1-C_5 alkyl, and C_1-C_5 alkylbiaryl, and which –C(O)aryl, aryl, aryl C_1-C_5 alkyl, and C_1-C_5 alkylbiaryl are each independently unsubstituted or substutited with from one to three substituents each independently selected from the group consisting of R13''; and

(t) R14' is a group consisting of halo, C1-C8alkyl, C_1-C_5 haloalkyl, C_1-C_5 alkoxy, and arylC_0-C_4alkyl; or

(u) a pharmaceutically acceptable salt thereof.

2. (Original) A compound as claimed by Claim 1 of the structural Formula II:



II

wherein R19 is selected from the group consisting of hydrogen, C1-C4alkyl, aryl, and arylmethyl, wherein the alkyl, aryl and arylmethyl are each unsubstituted or substituted with from one to three substituents each independently selected from R14'.

3. (Currently Amended) A compound as claimed by ~~any one of~~ Claims ~~1 to~~ 2 that is of the following structural formula III:



III

wherein R19 is selected from the group consisting of hydrogen, C1-C4alkyl, aryl, and arylmethyl, wherein the alkyl, aryl and arylmethyl are each unsubstituted or substituted with from one to three substituents each independently selected from R14'.

4. (Currently Amended) A compound as claimed by ~~any one of~~ Claims 1 ~~to 3~~ wherein R1 is ~~selected from the group consisting of~~ hydrogen. ~~C_1-C_4 alkyl, and arylC_0-C_4alkyl; R2 is selected from the group consisting of arylC_0-C_4alkyl, and heteroarylC_0-C_4alkyl.~~

5. (Currently Amended) A compound as claimed by ~~any one of~~ Claims ~~1 to~~ 4 wherein R2 is selected from the group consisting of arylC_0-C_4alkyl, C_1-C_8 alkyl, heteroarylC_0-C_4alkyl, C_3-C_6 cycloalkyl, C_0-C_4alkyl-C(O)-heteroC_1-C_8 alkyl, arylheteroC_1-C_8alkyl, wherein each of said R2 is unsubstituted or substituted by one or two substituents each independently selected from the group consisting of phenyl, halophenyl, phenoxy, halo, haloC_1-C_4 alkyl, C_1-C_4alkoxy, and C_3-C_6 cycloalkyl.

6. (Original) A compound as claimed by Claim 5 wherein R2 is arylC_0-C_4alkyl wherein the aryl is phenyl or napthyl, and the C_0-C_4alkyl is selected from the group consisting of methyl, ethyl and not present, that is C_0 alkyl.

7. (Original) A compound as claimed by Claim 5 wherein R2 is heteroarylC_0-C_4alkyl, and said heteroarylC_0-C_4alkyl is unsubstituted or substituted with from one to three substituents each independently selected from R2'; and wherein the heteroaryl is selected from the group consisting of pyridine, thiazole, benzothiazole, and thiadiazole; and the alkyl is selected from the group consisting of methyl, ethyl and not present, that is C_0 alkyl.

8. (Original) A compound as claimed by Claim 5 wherein R2 is arylheteroC$_1$-C$_8$alkyl, wherein the arylheteroC$_1$-C$_8$alkyl is unsubstituted or substituted with from one to three substituents each independently selected from the group consisting of R2'; wherein the aryl group is phenyl, and the heteroatom is selected from the group consisting of nitrogen, sulfur and oxygen.

9. (Currently Amended) A compound as claimed by ~~any one~~ of Claims ~~1 to~~ 8 wherein the R2 group is substituted with one or two substituents each independently selected from the group consisting of methyl, ethyl, t-butyl, fluorine, chlorine, bromine, trifluoromethyl, methoxyl, ethoxyl, phenyl, and phenoxyl.

10. (Canceled)

11. (Currently Amended) A compound as claimed by Claim ~~10~~ 1 wherein said piperidine and piperazine is fused with a phenyl to form a bicyclic ring.

12. (Currently Amended) A compound as claimed by ~~any one of~~ Claims 1, ~~to 9 5 or/Claims 7 to 9~~ wherein R2 is unsubstituted or substituted heteroarylC0-C4alkyl; wherein said heteroaryl is selected from the group consisting of:


, 
, 
, 
, 
, and.



13. (Canceled).

14. (Currently Amended) A compound as claimed by ~~any one of~~ Claims 1 ~~to 3, or 9 or 13~~ wherein R2 is -CH(C(O)OCH$_3$)benzyl.

15. (Currently Amended) A compound as claimed by ~~any one of~~ Claims 1 ~~to 14 12~~ or Claim 4 wherein R6 is selected from the group consisting of hydrogen, C$_1$-C$_4$ alkyl, and aryl-

C_{0-4}-alkyl, wherein the alkyl and arylalkyl are each independently substituted with from one to three substituents each independently selected from the group consisting of R5'.

16. (Currently Amended) A compound as claimed by ~~any one of~~ Claims ~~1 to 15 13~~ 15 wherein R5 is H or methyl.

17. (Currently Amended) A compound as claimed by any one of Claims 1 ~~to 14 12 or 16 14~~ or Claim 16 wherein R6 is C_1-C_3 alkyl.

18. (Currently Amended) A compound as claimed by ~~any one of~~ Claims ~~17 1 to 14 12 or 16 to 17 14 to 15~~, wherein R6 is methyl.

19. (Canceled)

20. (Currently Amended) A compound as claimed by ~~any one of~~ Claims 1 ~~or 4 to 18 16~~ wherein R5 is hydrogen or methyl, R6 is C_1-C_3 alkyl, ~~and E is C(R3)(R4)A,~~ and R3 is C_1-C_3alkoxy.

21. (Currently Amended) A compound as claimed by ~~any one of~~ Claims 1 ~~or 4 to 19 16~~ wherein ~~E is C(R3)(R4)A and~~ A is C(O)OR26; R26 is H or C_1-C_3alkyl.

22. (Currently Amended) A compound as claimed by ~~any one of~~ Claims 1~~, 4, 5, 10, or 15 to 20 13 to 18~~ that is of the structural formula IV:



IV



wherein R11 is selected from the group consisting of aryl, -C(O)aryl, haloC_1-C_5alkyloxy, C_1-C_5 alkylaryl, C_1-C_5 alkylbiaryl, aryloxy, and C1-C6 alkyl, wherein the aryl, -C(O)aryl, haloC_1-C_5alkyloxy, C_1-C_5 alkylaryl, C_1-C_5 alkylbiaryl, and C1-C6 alkyl are each independently unsubstituted or each independently substituted with from one to three substituents each independently selected from the group consisting of R1'.

23. (Currently Amended) A compound as claimed by ~~any one of~~ Claims ~~1 to 5, 10, 3 or 15 to 20~~ 13 to 18 that is of the structural formula V:



V



wherein R12 is selected from the group consisting of aryl, aryloxy, -C(O)aryl, haloC_1-C_5alkyloxy, C_1-C_5 alkylaryl, C_1-C_5 alkylbiaryl, and C1-C6 alkyl, wherein the aryl, -C(O)aryl, haloC_1-C_5alkyloxy, C_1-C_5 alkylaryl, C_1-C_5 alkylbiaryl, and C1-C6 alkyl are each independently unsubstituted or each independently substituted with from one to three substituents each independently selected from the group consisting of R1'.

24. (Canceled)

25. (Currently Amended) A compound as claimed by ~~any one of~~ Claims ~~1, 4, 5, 10, or 13 to 18~~ 12 to 16 that is of the structural formula VII:



VII

wherein wherein R12 is selected from the group consisting of aryl,aryloxy, -C(O)aryl, haloC_1-C_5alkyloxy, arylC_1-C_5 alkyl, C_1-C_5 alkylbiaryl, and C1-C6 alkyl, wherein the aryl, -C(O)aryl, aryloxy, haloC_1-C_5alkyloxy, C_1-C_5 alkylaryl, C_1-C_5 alkylbiaryl, and C1-C6 alkyl are each independently unsubstituted or each independently substituted with from one to three substituents each independently selected from the group consisting of R1'; R25 is selected from the group consisting of C1-C4alkyl, halo, haloC1-C3alkyl, C1-C5 alkoxy, and phenyl.

26. (Original) A compound as claimed by Claim 1 which is selected from the group consisting of:

(2S,1'R)-2-Ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid; (2S,1'R)-2-Ethoxy-3-(4-{1'-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;(2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S,1'R)-2-ethoxy-3-(4-{1'-[2-(2-ethoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S,1'R)-2-ethoxy-3-{4-[1'-(3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

(2S,1'R)-2-ethoxy-3-{4-[1'-(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

(2S,1'R)-3-(4-{1'-[(biphenyl-3-ylmethyl)-carbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-3-(4-{1'-[2-(3-chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-2-ethoxy-3-(4-{1'-[2-(3-fluoro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S,1'R)-2-ethoxy-3-(4-{1'-[2-(2-fluoro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S,1'R)-3-(4-{1'-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-3-(4-{1'-[2-(2,6-dichloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-3-(4-{1'-[2-(2-chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;(2S,1'R)-3-(4-{1'-[2-(4-tert-butyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-2-ethoxy-3-{4-[1'-(4-fluoro-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;(2S,1'R)-2-ethoxy-3-{4-[1'-(4-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

(2S,1'R)-3-{4-[1'-(4-tert-butyl-benzylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid;(2S,1'R)-3-{4-[1'-(4-tert-butyl-phenylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid;(2S,1'R)-3-{4-[1'-(4-trans-tert-butyl-cyclohexylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid;

(2S)-3-{4-[1-(4-tert-butyl-cyclohexylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid;

(2S)-2-methoxy-3-(4-{1-methyl-1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S)-3-(4-{1-[2-(2-ethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

2-methoxy-3-(4-{1-methyl-1-[2-(3-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S)-2-methoxy-3-{4-[1-methyl-1-(3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid; (2S)-3-(4-{1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[(biphenyl-3-ylmethyl)-carbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[2-(2,5-dimethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[2-(2-fluoro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-2-ethoxy-3-(4-{1-methyl-1-[2-(3-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S)-2-ethoxy-3-{4-[1-(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-1-methyl-ethoxy]-phenyl}-propionic acid;

(2S)-3-(4-{1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;(2S)-3-(4-{1-[(biphenyl-3-ylmethyl)-carbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-3-(4-{1-[2-(3-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-3-(4-{1-[2-(2,5-dimethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-2-ethoxy-3-(4-{1-[2-(2-fluoro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-propionic acid;

(2S)-3-{3-[1-(4-tert-butyl-cyclohexylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid;

(2S)-3-{3-[1-(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid;

(2S)-3-(3-{1-[(biphenyl-3-ylmethyl)-carbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(3-{1-[2-(3-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-2-methoxy-3-{4-[(1-phenyl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid;

(2S)-3-(3-{1-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(3-{1-[2-(2,6-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-3-(4-{1-[2-(2,6-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-2-ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-propionic acid;

(2S)-2-ethoxy-3-(4-{1-[2-(2-ethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-propionic acid;

2-Ethoxy-3-{4-[1-(3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

2-Ethoxy-3-{4-[1-(5-fluoro-3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

2-Ethoxy-3-{4-[1-(3-phenyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

2-Ethoxy-3-{4-[1-(4-phenoxy-phenylethylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

2-Ethoxy-3-{4-[1-(3-trifluoromethyl-phenylethylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

3-(4-{1-[2-(2,6-Dichloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

3-(4-{Cyclohexyl-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-2-ethoxy-propionic acid;

2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-2-phenyl-ethoxy}-phenyl)-propionic acid; and

(2S,1'R)-2-ethoxy-3-{4-[1'-(2-thiophen-2-yl-ethylcarbamoyl)-ethoxy]-phenyl}-propionic acid; or pharmaceutically acceptable salts thereof.

27. (Original) A compound as claimed by Claim 1 wherein the compound is selected from the group consisting of

(2S,1'R)-3-{4-[1'-(4-tert-butyl-cyclohexylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid;

(2S,1'R)-2-ethoxy-3-(4-{1'-[(thiophen-2-ylmethyl)-carbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S,1'R)-2-ethoxy-3-{4-[1'-(2-thiophen-2-yl-ethylcarbamoyl)-ethoxy]-phenyl}-propionic acid; or

pharmaceutically acceptable salts thereof.

28. (Original) A compound as claimed by Claim 1 wherein the compound is



; or a pharmaceutically acceptable salt thereof.

29. (Canceled)

30. (Currently Amended) A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and at least one compound as claimed by ~~any one of~~ Claims 1~~–29~~ or a pharmaceutically acceptable salt thereof.

31. (Canceled)

32. (Currently Amended) A method of treating diabetes mellitus in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of at least one compound of Claims 1~~–29~~ or a pharmaceutically acceptable salt thereof.

33. (Currently Amended) A method of preventing diabetes mellitus in a mammal, comprising the step of administering to the mammal an effective amount of at least one compound of Claims 1~~–29~~ or a pharmaceutically acceptable salt thereof.

34. (Currently Amended) A method of treating Syndrome X in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of at least one compound of Claims 1~~–29~~ or a pharmaceutically acceptable salt thereof.

35. (Canceled)

36. (Currently Amended) A compound or pharmaceutically acceptable salt thereof according to ~~any one of~~ Claims 1 ~~through 29~~ for use as a medicine.

37. (Canceled)

38. (Canceled)

39. (Canceled)

40. (New Claim) A compound of the formula



; or a pharmaceutically acceptably salt thereof.

41. (New Claim) A Compound of the formula



Wherein R1 is selected from the group consisting of hydrogen, C_1-C_4alkyl and arylC_0-C_4alkyl; R2 is selected from the group consisting of arylC_0-C_4alkyl, and heteroarylC_0-C_4alkyl; or a pharmaceutical acceptable salt thereof.

42. (New Claim) A compound as claimed by Claim 1 that is of the formula:



or a pharmaceutically acceptable salt thereof.

43. (New Claim) A compound as claimed by any one of Claims 1, or 42 wherein the compound is a pharmaceutically acceptable salt.

44. (New Claim) A compound of Claim 1 that is (2S)-3-(4-{[2-(2,6-dichloro-benzylsulfanyl)-ethylcarbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid.

45. (New Claim) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound as claimed by Claim 42 or 44.